## For Research Use Only

## TDP-43 Polyclonal antibody Catalog Number:10782-2-AP Featured Product 15

Featured Product 1591 Publications




Basic Information	Catalog Number: 10782-2-AP	GenBank Accession Number: BC001487 GeneID (NCBI): 23435 UNIPROT ID: Q13148 Full Name: TAR DNA binding protein Calculated MW: 43 kDa Observed MW: 44 kDa		Purification Method: Antigen affinity purification Recommended Dilutions: WB: 1:2000-1:10000 IP: 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate IHC: 1:2000-1:8000 IF-fro: 1:1000-1:4000 IF/ICC: 1:3000-1:12000 FC (Intra): 0.40 ug per 10^6 cells in a 100 µl suspension ChIP: 1:10-1:100	
	Size: 150ul , Concentration: 600 ug/ml by				
	Nanodrop; Source:				
	Rabbit Isotype: IgG				
Applications	Tested Applications:	Positive Controls:		rols:	
	WB, IHC, IF/ICC, IF-Fro, FC (Intra), IP, ChIP, ELISA Cited Applications: WB, IHC, IF, IP, CoIP, ChIP, RIP, ELISA, IEM Species Specificity: human, mouse, rat, zebrafish Cited Species: human, mouse, rat, monkey, chicken, zebrafish,		cells		
			IHC : human g	IP : HeLa cells, IHC : human gliomas tissue, human brain (FTLD-U) tissue, mourse brain tissue,	
			IF-Fro: rat bra	tissue, mouse brain tissue IF-Fro : rat brain tissue, mouse brain tissue	
	hamster, yeast, horse, seal Note-IHC: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0			IF/ICC : HeLa cells, FC (Intra) : HeLa cells,	
			ChIP : HeLa ce	ChIP: HeLa cells,	
Background Information	TDP-43 has since been shown to bind translational regulation and pre-mR gene. In 2006 Neumann et al. found i collectively known as pathological 1 and alpha-synuclein-negative frontc Proteintech's 10782-2-AP antibody is intact 43 kDa protein as well as all p Various forms of TDP-43 exist, include	d RNA as well as DI NA splicing. For ins that hyperphospho IDP-43, play a maj otemporal dementi s a rabbit polyclon osttranslationally ding 18-35 kDa of c rphosphorylated for 43 has been report	NA, and have multip stance, it is reported rylated, ubiquitinate or role in the disease a (FTLD-U) and in an al antibody recogniz modified and trunca cleaved C-terminal f orm, and 90-300 kDa ed to be overexpress	e mechanisms of ubiquitin-positive, ta nyotrophic lateral sclerosis (ALS). ing N-terminal TDP-43. It recognizes th ted forms in multiple applications. ragments, 45-50 kDa phospho-protein, cross-linked form. (17023659, 198238 sed in triple negative breast cancer	
	TDP-43 has since been shown to bind translational regulation and pre-mR gene. In 2006 Neumann et al. found 1 collectively known as pathological 1 and alpha-synuclein-negative frontc Proteintech's 10782-2-AP antibody is intact 43 kDa protein as well as all p Various forms of TDP-43 exist, includ kDa glycosylated form, 75 kDa hype 21666678, 22193176) Recently TDP- (TNBC) and it may be a potential tar	d RNA as well as DI NA splicing. For ins that hyperphospho IDP-43, play a maj otemporal dementi s a rabbit polyclon osttranslationally ding 18-35 kDa of c rphosphorylated for 43 has been report	NA, and have multip stance, it is reported rylated, ubiquitinate or role in the disease a (FTLD-U) and in an al antibody recogniz modified and trunca cleaved C-terminal f orm, and 90-300 kDa ed to be overexpress	le functions in transcriptional repression to regulate alternate splicing of the CT ed and/or cleaved forms of TDP-43, the mechanisms of ubiquitin-positive, ta nyotrophic lateral sclerosis (ALS). ing N-terminal TDP-43. It recognizes the ted forms in multiple applications. ragments, 45-50 kDa phospho-protein, cross-linked form. (17023659, 198238) sed in triple negative breast cancer	
	TDP-43 has since been shown to bind translational regulation and pre-mRi gene. In 2006 Neumann et al. found i collectively known as pathological 1 and alpha-synuclein-negative frontc Proteintech's 10782-2-AP antibody is intact 43 kDa protein as well as all p Various forms of TDP-43 exist, includ kDa glycosylated form, 75 kDa hype 21666678, 22193176) Recently TDP- (TNBC) and it may be a potential tarp Author P	d RNA as well as DI NA splicing. For ins that hyperphospho TDP-43, play a maj otemporal dementi s a rabbit polyclon iosttranslationally ding 18-35 kDa of c rphosphorylated fc 43 has been report get for TNBC diagn	NA, and have multip stance, it is reported rylated, ubiquitinate or role in the disease (FTLD-U) and in an al antibody recogniz modified and trunca leaved C-terminal f orm, and 90-300 kDa ed to be overexpress osis and drug design	le functions in transcriptional repression to regulate alternate splicing of the CT ed and/or cleaved forms of TDP-43, e mechanisms of ubiquitin-positive, tau nyotrophic lateral sclerosis (ALS). ing N-terminal TDP-43. It recognizes the ted forms in multiple applications. ragments, 45-50 kDa phospho-protein, cross-linked form. (17023659, 1982385 sed in triple negative breast cancer A. (29581274) Application	
	TDP-43 has since been shown to bind translational regulation and pre-mR gene. In 2006 Neumann et al. found 1 collectively known as pathological 1 and alpha-synuclein-negative frontc Proteintech's 10782-2-AP antibody is intact 43 kDa protein as well as all p Various forms of TDP-43 exist, includ kDa glycosylated form, 75 kDa hype 21666678, 22193176) Recently TDP- (TNBC) and it may be a potential tarp Author P Kasey LJackson 2	d RNA as well as DI NA splicing. For ins that hyperphospho IDP-43, play a maj otemporal dementi s a rabbit polyclon oosttranslationally ding 18-35 kDa of of rphosphorylated fo 43 has been report get for TNBC diagn	NA, and have multip stance, it is reported rylated, ubiquitinate or role in the disease a (FTLD-U) and in an al antibody recogniz modified and trunca cleaved C-terminal f prm, and 90-300 kDa ed to be overexpress osis and drug design	le functions in transcriptional repression to regulate alternate splicing of the CT ed and/or cleaved forms of TDP-43, e mechanisms of ubiquitin-positive, ta nyotrophic lateral sclerosis (ALS). ing N-terminal TDP-43. It recognizes th ted forms in multiple applications. ragments, 45-50 kDa phospho-protein, cross-linked form. (17023659, 198238) sed in triple negative breast cancer A. (29581274) Application	
	TDP-43 has since been shown to bind translational regulation and pre-mR gene. In 2006 Neumann et al. found 1 collectively known as pathological 1 and alpha-synuclein-negative frontoc Proteintech's 10782-2-AP antibody is intact 43 kDa protein as well as all p Various forms of TDP-43 exist, incluc kDa glycosylated form, 75 kDa hype 21666678, 22193176) Recently TDP- (TNBC) and it may be a potential tarpAuthorP Kasey L Jackson2Jinwal Umesh K UK1	d RNA as well as DI NA splicing. For ins that hyperphospho TDP-43, play a maj otemporal dementi s a rabbit polyclon iosttranslationally ding 18-35 kDa of c rphosphorylated fo 43 has been report get for TNBC diagn ubmed ID 6445725	NA, and have multip stance, it is reported rylated, ubiquitinate or role in the disease a (FTLD-U) and in an al antibody recogniz modified and trunca cleaved C-terminal for mm, and 90-300 kDa ed to be overexpress osis and drug design Journal Mol Ther Methods C	le functions in transcriptional repressi to regulate alternate splicing of the C ed and/or cleaved forms of TDP-43, e mechanisms of ubiquitin-positive, ta nyotrophic lateral sclerosis (ALS). ing N-terminal TDP-43. It recognizes th ted forms in multiple applications. ragments, 45-50 kDa phospho-protein, cross-linked form. (17023659, 198238) sed in triple negative breast cancer a. (29581274) Application lin Dev WB	
Background Information	TDP-43 has since been shown to bind translational regulation and pre-mR gene. In 2006 Neumann et al. found 1 collectively known as pathological 1 and alpha-synuclein-negative frontc Proteintech's 10782-2-AP antibody is intact 43 kDa protein as well as all p Various forms of TDP-43 exist, incluc kDa glycosylated form, 75 kDa hype 21666678, 22193176) Recently TDP- (TNBC) and it may be a potential tarp Author P Kasey L Jackson 2 Jinwal Umesh K UK 1	d RNA as well as DI NA splicing. For inst that hyperphospho IDP-43, play a maj otemporal dementi s a rabbit polyclon. iosttranslationally ding 18-35 kDa of c rphosphorylated for 43 has been report get for TNBC diagn ubmed ID 6445725 9793966 3003404 iter shipment.	NA, and have multip stance, it is reported rylated, ubiquitinate or role in the disease a (FTLD-U) and in an al antibody recogniz modified and trunca tleaved C-terminal f orm, and 90-300 kDa ed to be overexpress osis and drug design <b>Journal</b> Mol Ther Methods C J Neurosci Cells	le functions in transcriptional repression to regulate alternate splicing of the CT ed and/or cleaved forms of TDP-43, e mechanisms of ubiquitin-positive, ta nyotrophic lateral sclerosis (ALS). ing N-terminal TDP-43. It recognizes th ted forms in multiple applications. ragments, 45-50 kDa phospho-protein, cross-linked form. (17023659, 198238) sed in triple negative breast cancer h. (29581274) Application lin Dev WB	

in USA), or 1(312) 455-8498 (outside USA)


W: ptglab.com

other manufacturer.


## Selected Validation Data




Chromatin was prepared from HeLa cells, cells were fixed with formaldehyde for 10 minutes. The ChIP was performed with 15 µg of cross-linked chromatin, 5 µg of TDP-43 Antibody(10782-2-AP) or 5 µg of Normal Rabbit IgG (30000-0-AP), and 30 µl of Protein A Magarose Beads. The immunoprecipitated DNA was quantified by real time PCR. Primers are located in the first kb of the transcribed region.




40X of FTLD-U case stained by 10782-2-AP and 60019-2-1g, showing dystrophic neurites. (Figs were provided by Linda K. Kwong).



Various lysates were subjected to SDS PAGE followed by western blot with 10782-2-AP (TDP-43 antibody) at dilution of 1:5000 incubated at room temperature for 1.5 hours.




Immunohistochemical analysis of paraffinembedded mouse brain tissue slide using 10782-2-AP (TDP-43 (N-terminal) antibody) at dilution of 1:5000 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).





Immunohistochemical analysis of paraffinembedded human gliomas tissue slide using 10782-2-AP (TDP-43 antibody) at dilution of 1:4000 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).




Immunohistochemical analysis of paraffinembedded human gliomas tissue slide using 10782-2-AP (TDP-43 antibody) at dilution of 1:4000 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).









Immunohistochemical analysis of paraffinembedded mouse brain tissue slide using 10782-2-AP (TDP-43 antibody) at dilution of 1:2000 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).




WB result of TDP-43 antibody (10782-2-AP; 1:30000; incubated at room temperature for 1.5 hours) with sh-Control and sh-TDP-43 transfected HeLa cells.









Immunohistochemical analysis of paraffinembedded mouse brain tissue slide using 10782-2-AP (TDP-43 antibody) at dilution of 1:2000 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0). IP result of anti-TDP-43 (IP:10782-2-AP, 4ug; Detection:10782-2-AP 1:50000) with HeLa cells lysate 1520 ug. Immunofluorescent analysis of (4% PFA) fixed HeLa cells using TDP-43 antibody (10782-2-AP) at dilution of 1:6000 and CoraLite@488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L), CL594phalloidin (red).



1X10^6 HeLa cells were intracellularly stained with 0.4 ug Anti-Human TDP-43 (10782-2-AP) and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L) at dilution 1:1000 (red), or 0.4 ug Isotype Control. Cells were fixed and permeabilized with Transcription Factor Staining Buffer Kit (PF00011).



Immunofluorescent analysis of (4% PFA) fixed frozen OCT-embedded rat brain tissue using TDP-43 antibody (10782-2-AP) at dilution of 1:2000 and CoraLite® 488-Conjugated Goat Anti-Rabbit IgG(H+L) (SA00013-2), CoraLite® 594 GFAP antibody (CL594-16825, red).



Immunofluorescent analysis of (4% PFA) fixed frozen OCT-embedded mouse brain tissue using TDP-43 antibody (10782-2-AP) at dilution of 1:2000 and CoraLite®647-conjugated F(ab, MAP2 antibody (67015-1-Ig, Clone: 1C3E6, green), CoraLite®594 GFAP antibody (CL594-16825, red).